http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Fleitas, Tania (검색결과 1 건)
- 무료
- 기관 내 무료
- 유료
-
Meulendijks, Didier,Jacob, Wolfgang,Voest, Emile E.,Mau-Sorensen, Morten,Martinez-Garcia, Maria,Taus, Alvaro,Fleitas, Tania,Cervantes, Andres,Lolkema, Martijn P.,Langenberg, Marlies H.G.,De Jonge, Maj American Association for Cancer Research 2017 Clinical Cancer research Vol.23 No.18
<P><B>Purpose:</B> This study investigated the safety, clinical activity, and target-associated biomarkers of lumretuzumab, a humanized, glycoengineered, anti-HER3 monoclonal antibody (mAb), in combination with the EGFR-blocking agents erlotinib or cetuximab in patients with advanced HER3-positive carcinomas.</P><P><B>Experimental Design:</B> The study included two parts: dose escalation and dose extension phases with lumretuzumab in combination with either cetuximab or erlotinib, respectively. In both parts, patients received lumretuzumab doses from 400 to 2,000 mg plus cetuximab or erlotinib according to standard posology, respectively. The effect of <I>HRG</I> mRNA and <I>HER3</I> mRNA and protein expression were investigated in a dedicated extension cohort of squamous non–small cell lung cancer (sqNSCLC) patients treated with lumretuzumab and erlotinib.</P><P><B>Results:</B> Altogether, 120 patients were treated. One dose-limiting toxicity (DLT) in the cetuximab part and two DLTs in the erlotinib part were reported. The most frequent adverse events were gastrointestinal and skin toxicities, which were manageable. The objective response rate (ORR) was 6.1% in the cetuximab part and 4.2% in the erlotinib part. In the sqNSCLC extension cohort of the erlotinib part, higher tumor <I>HRG</I> and <I>HER3</I> mRNA levels were associated with a numerically higher disease control rate but not ORR.</P><P><B>Conclusions:</B> The toxicity profile of lumretuzumab in combination with cetuximab and erlotinib was manageable, but only modest clinical activity was observed across tumor types. In the sqNSCLC cohort, there was no evidence of meaningful clinical benefit despite enriching for tumors with higher <I>HRG</I> mRNA expression levels. <I>Clin Cancer Res; 23(18); 5406–15. ©2017 AACR</I>.</P>
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
